CLL Coverage from Every Angle

Matthew S. Davids, MD, on Sequence of Administration of Ibrutinib Plus Obinutuzumab for CLL

Posted: Saturday, September 12, 2020

Matthew S. Davids, MD, of Dana-Farber Cancer Institute, discusses phase Ib data showing that obinutuzumab incidence rate ratios in relapsed or refractory chronic lymphocytic leukemia were higher with obinutuzumab started prior to ibrutinib, compared with starting ibrutinib prior to obinutuzumab or starting both drugs simultaneously.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.